APA (7th ed.) Citation

R, L., PH, S., TF, S., JK, N., TJ, B., DL, L., . . . GD, S. (2024). Author Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial. Nature medicine, 30(8), 2372. https://doi.org/10.1038/s41591-024-03137-w

Chicago Style (17th ed.) Citation

R, Li, et al. "Author Correction: Oncolytic Adenoviral Therapy Plus Pembrolizumab in BCG-unresponsive Non-muscle-invasive Bladder Cancer: The Phase 2 CORE-001 Trial." Nature Medicine 30, no. 8 (2024): 2372. https://doi.org/10.1038/s41591-024-03137-w.

MLA (9th ed.) Citation

R, Li, et al. "Author Correction: Oncolytic Adenoviral Therapy Plus Pembrolizumab in BCG-unresponsive Non-muscle-invasive Bladder Cancer: The Phase 2 CORE-001 Trial." Nature Medicine, vol. 30, no. 8, 2024, p. 2372, https://doi.org/10.1038/s41591-024-03137-w.